Spark Therapeutics says it will charge $850,000 for its new gene therapy for blindness, the Irish Times reports, making it the most expensive drug on the market.
Jeff Marrazzo, Spark Therapeutics' CEO, said the company would charge $425,000 for each eye for Luxturna, the first gene therapy to be approved by the Food and Drug Administration.
That's less than the $1 million the company hinted at just a few weeks ago.
Unlike traditional drugs, gene therapies are one-off treatments that repair faulty DNA so the body can fix itself.
Spark’s Luxturna involves inserting a functioning copy of a missing gene directly into a patient’s eye, where it encourages the body to produce a protein essential for sight.
In clinical trials, the medicine restored eyesight in some people with severe visual impairment.
Read the full story: